Kiniksa Pharmaceuticals International, plc (KNSA)

Market Cap	2.62B
Revenue (ttm)	529.33M
Net Income (ttm)	4.79M
Shares Out	74.11M
EPS (ttm)	0.07
PE Ratio	535.24
Forward PE	25.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214,262
Open	35.30
Previous Close	35.48
Day's Range	35.06 - 35.59
52-Week Range	17.82 - 35.59
Beta	0.20
Analysts	Strong Buy
Price Target	40.83 (+15.6%)
Earnings Date	Oct 28, 2025

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA
• Website: https://www.kiniksa.com

Analyst Summary

According to 6 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $40.83, which is an increase of 15.60% from the latest price.

Price Target

$40.83

(15.60% upside)

Analyst Consensus: Strong Buy